Should we be utilizing prophylactic G-CSF in our patients with intermediate risk of febrile neutropenia due to the COVID-19 pandemic?  

Are you placing more weight on patient risk factors such as age >65 or co-morbidities?



Answer from: at Academic Institution

Answer from: Medical Oncologist at Academic Institution